Featured News
-
NMD Pharma Shares New SYNAPSE-CMT Trial Data -
How One Family Turned Heartbreak Into Hope -
NMD Pharma Announces CMT Trial Results -
When Early Testing Shows a Program Is Worth Continuing -
Reproductive Choices in CMT -
![ACT-CMT: The Largest-Ever Study of CMT Opens [Casting] Call for More Participants](https://cmtausa.org/wp-content/uploads/2025/12/12.10.25-Blog.png)
ACT-CMT Expands: Call for New CMT1A Participants -
Particles on a Mission: Can Nanoparticles Solve One of CMT’s Largest Hurdles? -
What Can Long-Read Sequencing Reveal About CMT? -
CMTA Names Dr. Michelassi at UVA as Center of Excellence
All News
Search Simply CMT by Category
-
Prof. Mary Reilly Honored with Prestigious MBE for CMT WorkThe Charcot-Marie-Tooth Association proudly celebrates Professor Mary M. Reilly, MD, CMTA-STAR Clinical Expert Board Co-Chair,…
Published: February 18, 2025
-
CMT-SORD: Bringing the Science Down to EarthShooting Star brings science down to Earth, making complex CMT topics easy to understand. Created…
Published: February 14, 2025
-
Learn How CMTA is Accelerating Research and Empowering PatientsThe Charcot-Marie-Tooth Association (CMTA) is transforming the future of CMT research, CMT treatments, and CMT…
Published: February 13, 2025
-
Simply CMT Podcast Episode 2: Jonah BergerWelcome to Episode 2 of the Simply CMT Podcast! Join us as we talk with Jonah…
Published: February 4, 2025
-
CMTA Invests $423K to Accelerate CMT Gene Discovery and DiagnosticsCMTA announced today a $423,000 investment to address diagnostic gaps and drive new CMT gene…
Published: February 4, 2025
-
Nervosave: Shaping the Future of Genetic Therapy for CMT1AWhat is the Nervosave Survey? CMTA-STAR Alliance Partner Nervosave Therapeutics, a France-based biotech company, is…
Published: January 23, 2025
-
CMTA’s New Video Aims to Increase Awareness About CMTCharcot-Marie-Tooth disease (CMT) is the most common inheritable peripheral neuropathy, affecting millions of people worldwide.…
Published: January 23, 2025
-
Encouraging CMT Research Update from CMTA-STAR Partner AlestaAlesta Therapeutics, a CMTA-STAR Alliance Partner focused on developing therapies for rare diseases, recently announced…
Published: January 23, 2025
-
NMD Pharma’s NMD670 for CMT Earns FDA Orphan Drug DesignationNMD Pharma A/S, a CMTA-STAR Alliance Partner, recently announced that the U.S. Food and Drug…
Published: January 22, 2025
-
CMTA Partner NMD Pharma Publishes Study, SYNAPSE-CMT RecruitingCMTA-STAR Alliance Partner NMD Pharma A/S has announced the publication of foundational findings in the Annals…
Published: December 18, 2024
-
CMTA Announces New Center of Excellence at Virginia Commonwealth UniversityCMTA has designated a new Center of Excellence at Virginia Commonwealth University, expanding access to…
Published: December 17, 2024
-
SYNAPSE-CMT Phase II Trial BeginsThe Phase II SYNAPSE-CMT clinical trial has launched, with the first patient dosed at a…
Published: November 20, 2024
